Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70735 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Desiree Kunadt und 55 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Aniline Compounds. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany.
- Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Gießen and Marburg, Marburg, Germany.
- Department of Hematology, Oncology and Pneumology, University Medical Center Mainz, Mainz, Germany.
- Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany.
- Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
- University Hospital Eppendorf, Hamburg, Germany.
ORCID-Profile: Desiree Kunadt, Sven Zukunft, Christoph Röllig, Oliver Kriege, Christoph Schliemann, Julian Ronnacker, Wolfgang Bethge, Jan Frederic Weller, Gesine Bug, Khouloud Kouidri, Claudia Baldus, Lars Fransecky, Uwe Platzbecker, Klaus Metzeler, Inken Hilgendorf, Tim H Brümmendorf, Anna Dorottya Doleschall, Udo Holtick, Julia M Unglaub, Paul Sebastian Jäger, Guido Kobbe, Tobias Herold, Normann Steiner, Jochen J Frietsch, Sabrina Kraus, Hermann Einsele, Mathias Hänel, William Krüger, Anne Brandenburg, Tobias A W Holderried, Markus Maulhardt, Christian Thiede, Martin Bornhäuser, Johannes Schetelig, Friedrich Stölzel
Zitieren
APA
Kunadt, D., Zukunft, S., Röllig, C., Metzelder, S., Burchert, A., Wagner-Drouet, E., Kriege, O., Schliemann, C., Stelljes, M., Ronnacker, J., Bethge, W., Weller, J. F., Steffen, B., Bug, G., Kouidri, K., Baldus, C., Fransecky, L., Sala, E., Platzbecker, U., …, & German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL) (2026). Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study. British Journal of Haematology. https://doi.org/10.1111/bjh.70735
Vancouver
Kunadt D, Zukunft S, Röllig C, Metzelder S, Burchert A, Wagner-Drouet E, et al. Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study. British Journal of Haematology. 2026. doi:10.1111/bjh.70735
BibTeX
@article{Kunadt2026,
author = {Kunadt, Desiree and Zukunft, Sven and Röllig, Christoph and Metzelder, Stephan and Burchert, Andreas and Wagner-Drouet, Eva and Kriege, Oliver and Schliemann, Christoph and Stelljes, Matthias and Ronnacker, Julian and Bethge, Wolfgang and Weller, Jan Frederic and Steffen, Björn and Bug, Gesine and Kouidri, Khouloud and Baldus, Claudia and Fransecky, Lars and Sala, Elisa and Platzbecker, Uwe and Metzeler, Klaus and Kayser, Sabine and Hilgendorf, Inken and Hochhaus, Andreas and Brümmendorf, Tim H and Jost, Edgar and Doleschall, Anna Dorottya and Schroeder, Thomas and Kaivers, Jennifer and Kordelas, Lambros and Holtick, Udo and Unglaub, Julia M and Sauer, Tim and Jäger, Paul Sebastian and Kobbe, Guido and Stauffer, Elena and Tischer, Johanna and Herold, Tobias and Steiner, Normann and Nachbaur, David and Kröger, Nicolaus and Frietsch, Jochen J and Kraus, Sabrina and Einsele, Hermann and Hänel, Mathias and Schaffrath, Judith and Krüger, William and Brandenburg, Anne and Holderried, Tobias A W and Reinhardt, Laura and Maulhardt, Markus and Thiede, Christian and Bornhäuser, Martin and Schetelig, Johannes and Middeke, Jan M and Stölzel, Friedrich and German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL), German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)},
title = {Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70735}
}
EUVIMED